

Supplementary Materials

Table S1. Baseline clinical characteristics of the patients.

| Study | ELN intermediate - % | Normal karyotype - % | Bone marrow blasts – % (range) | Hemoglobin (g/dl) – mean (range) | White blood cells (10 ³ /μl) – mean (range) | Platelets (10 ³ /μl) – mean (range) |
|---------------------------|----------------------------|----------------------------|--------------------------------------|--|--|--|
| Aiba, 2023 [28] | nr | nr | nr | nr | nr | nr |
| Apel, 2021 [29] | 42 | 35 | 40 | 9 | 5 | 73 |
| Begna, 2021 [30] | nr | nr | nr | nr | nr | nr |
| Cherry, 2021 [31] | 17 | nr | 50 (10-97) | nr | nr | nr |
| De Bellis, 2022 [21] | 55 | 38 | 55 (20-100) | 9 (4-15) | 5 (<1-109) | 39 (7-351) |
| Feld, 2021 [32] | 43 | nr | 25 | 9 | 5 | 58 |
| Fleishmann, 2022 [33] | 30 | 32 | nr | nr | 12 (<1-317) | nr |
| Garciaz, 2022 [34] | nr | nr | 36 (7-88) | nr | 4 (<1-63) | 90 (3-365) |
| Kwang, 2022 [35] | 61 | nr | 51 | nr | nr | nr |
| Matthews, 2022 [26] | nr | nr | nr | nr | nr | nr |
| Mirgh, 2021 [36] | 63 | 42 | nr | 8 (5-11) | nr | nr |
| Morsia, 2020 [37] | 27 | 41 | 35 (20-95) | 9 (5-14) | 4 (1-97) | 73 (10-444) |
| Mustafa Ali, 2022 [38] | 82 | nr | nr | nr | nr | nr |
| Salhotra, 2021 [39] | 20 | nr | 41 (20-90) | nr | 15 (<1-127) | 110 (6-771) |
| Shah, 2022 [40] | nr | nr | 27 | 9 | 3 | 87 |
| Todisco, 2023 [24] | 54 | nr | 40 | 9 | 6 | 43 |
| Vachhani, 2022 [27] | 22 | nr | nr | nr | nr | nr |
| Venugopal, 2021 [41] | nr | 3 | 33 (8-88) | nr | 3 (1-73) | 34 (5-136) |
| Winters, 2019 [42] | 10 | nr | 55 | nr | 3 | nr |
| DiNardo, 2020 [14] | nr | 44 | <30% 30%-50% 50% | 30% 21% 49% | With Anemia 31% | With Neutropenia 72% |
| | | | | | | With Thrombocytopenia 51% |

ELN: European LeukemiaNet risk classification; nr not reported for the considered subgroup.

Table S2. Reported Adverse Events (AE).

| Study | N. patients | Neutropenia grade 3/4 - % | Thrombocytopenia - % | Febrile neutropenia - % | TLS - % | Discontinuation for AE - % |
|------------------------|------------------------|--|---------------------------------|------------------------------------|----------------|---------------------------------------|
| Aiba, 2023 [28] | 13 | nr | nr | 80 | nr | nr |
| Apel, 2021 [29] | 133 | 88 | 75 | 62 | 12 | 8 |
| Begna, 2021 [30] | 28 | nr | nr | nr | nr | nr |
| Cherry, 2021 [31] | 143 | nr | nr | nr | nr | nr |
| De Bellis, 2022 [21] | 51 | 29 | 14 | 13 | 0 | 55 |
| Feld, 2021 [32] | 72 | 72 | nr | 47 | 6 | 35 |
| Fleishmann, 2022 [33] | 17 | 45 | 15 | nr | 12 | 29 |
| Garciaz, 2022 [34] | 39 | nr | nr | nr | nr | nr |
| Kwang, 2022 [35] | 74 | nr | nr | nr | 1 | 7 |
| Matthews, 2022 [26] | 129 | 31 | 30 | 54 | nr | nr |
| Mirgh, 2021 [36] | 24 | 70 | 38 | 33 | 1.8 | 66 |
| Morsia, 2020 [37] | 44 | nr | nr | nr | nr | 30 |
| Mustafa Ali, 2022 [38] | 51 | nr | nr | nr | nr | nr |
| Salhotra, 2021 [39] | 30 | nr | nr | nr | nr | nr |
| Shah, 2022 [40] | 48 | nr | nr | nr | nr | nr |
| Todisco, 2023 [24] | 43 | 37 | 21 | 19 | 0 | 11 |
| Vachhani, 2022 [27] | 169 | 26 | nr | nr | nr | 12 |
| Venugopal, 2021 [41] | 58 | nr | nr | nr | nr | nr |
| Winters, 2019 [42] | 30 | 93 | 90 | 47 | nr | nr |
| DiNardo, 2020 [14] | 286 | 42 | 45 | 42 | 1 | 24 |

nr: not reported for the considered subgroup; TLS: tumor lysis syndrome.

Table S3. *p*-values of the log-rank test for the pairwise comparisons between single studies and DiNardo et al.

| Study | p-value |
|------------------------|----------------|
| Aiba, 2023 [28] | 0.5651 |
| Apel, 2021 [29] | 0.0136 |
| Begna, 2021 [30] | 0.1734 |
| Cherry, 2021 [31] | 0.5787 |
| De Bellis, 2022 [21] | 0.5207 |
| Feld, 2021 [32] | 0.0873 |
| Fleishmann, 2022 [33] | 0.6061 |
| Garciaz, 2022 [34] | 0.0585 |
| Kwang, 2022 [35] | 0.6534 |
| Matthews, 2022 [26] | 0.0259 |
| Mirgh, 2021 [36] | 0.4590 |
| Morsia, 2020 [37] | 0.1707 |
| Mustafa Ali, 2022 [38] | 0.0013 |
| Salhotra, 2021 [39] | 0.3333 |
| Shah, 2022 [40] | 0.1420 |
| Todisco, 2023 [24] | 0.0249 |
| Vachhani, 2022 [27] | <0.0001 |
| Venugopal, 2021 [41] | <0.0001 |
| Winters, 2019 [42] | 0.0001 |




Figure S1. Flowchart.





Figure S2. Pairwise comparisons between the study of DiNardo and the real-world studies.



* the studies of Sahah et al., Salhotra et al. and Venogupal et al. were excluded from this analysis

Figure S3. Pooled survival curve after the exclusion of high-risk patients *, compared with that of DiNardo et al.




Figure S4. Leave-one-out analysis.